Facebook
Twitter
LinkedIn
ForwardMCI Multispecialty Grand Rounds – An Update on Immunotherapy for Glioblastoma: Getting Personal
Immunotherapy has emerged as a cornerstone of modern oncology with regulatory approvals for a variety of immunotherapeutic being achieved for a spectrum of cancer indications. Nonetheless the role of these approaches for patients with glioblastoma (GBM), the most common and deadliest primary malignant brain neoplasm, remains unknown.
During this lecture Dr. Reardon will help participants understand the results of major immunotherapy trials for glioblastoma and comprehend strategies for personalizing immunotherapy approaches.
Locations
| Live- MCI – Tumor Board Room - 3N 110 |
| Webcast |
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetrics and Gynecologists, Oncologists, Radiation Oncologists, Nurses, Social Workers, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Summarize the results of major immunotherapy trials for glioblatoma to date.
- Identify factors associated with immunosuppression in glioblastoma.
- Implement strategies for personalizing immunotherapy approaches.
David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
David A. Reardon, M.D., indicated that neither he has received Grant/Research Support from: Acerta Pharmaceuticals, Agenus, Celdex, EMD Serono, Incyte, Inovia and Midatech. Dr. Reardon is a consultant for Abbvie, Advantagene, Amgem, Agenus, Boehringer Ingelheim and Bristol-Myers Squibb. Dr. Reardon is also on the speakers bureau for Cancer Research Institute and Institute for international Medicine (INMED), and he will not include off-label or unapproved product usage in her presentation(s) or discussion(s).
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine and Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nursing, Nurse Practitioners, Clinical Chaplains, Pharmacy and Respiratory Care (personal growth). Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Occupational Therapy
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
NOTE: Due to limited space, this conference is open to Baptist Health affiliated Medical Staff and Clinical Employees.
Required Hardware/Software
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.